Jackson Square Partners Trims Its Holdings in Pacific Biosciences – Industry Experts Eye 24.83% Growth Potential

Investment Changes at Pacific Biosciences of California

Jackson Square Partners Trims Its Holdings

Fintel, a finance news outlet, recently reported that Jackson Square Partners has filed a 13G/A form with the Securities and Exchange Commission (SEC) revealing their ownership of 15.01 million shares of Pacific Biosciences of California Inc (PACB). This translates to 6.64% of the company’s total shares.

In contrast to their previous filing on February 7, 2022, which indicated that they held 22.42 million shares, equating to 10.17% ownership, there has been a noticeable decline of 33.08% in shares and 3.53% in overall ownership.

As of February 10, 2023, the average one-year price target for Pacific Biosciences of California is $12.50, reflecting a growth of 24.83% from its most recent closing price of $10.01. The estimated annual revenue for the company is expected to reach $180 million, signifying an increase of 31.68%.

In the last quarter, there has been a decrease of 3.49% in ownership, with 16 fewer owners. The average weight of all funds invested in PACB has increased by 93.76%, standing at 0.17%. The total number of shares owned by institutional investors has declined by 9.88% to 258,839K shares in the past three months.

ARK Investment Management currently holds 25,692K shares, which translates to 9.84% ownership of the company. In their previous filing, the firm reported owning 28,692K shares, indicating a drop of 11.68%. However, their allocation in PACB has increased by 56.87% in the last quarter.

The ARK Innovation ETF, ARKK, holds 14,456K shares, equivalent to 5.54% ownership of the company. In their prior filing, the firm reported owning 14,079K shares, an increase of 2.61%. The firm has also increased their allocation in PACB by 141.30% in the last quarter.

Nikko Asset Management Americas currently holds 14,392K shares, equating to 5.51% ownership of the company. In their previous filing, the firm reported owning 14,345K shares, a slight increase of 0.32%. Their portfolio allocation in PACB has increased by 43.35% in the last quarter.

Sumitomo Mitsui Trust Holdings currently holds 14,166K shares, which translates to 5.43% ownership of the company. In their prior filing, the firm reported owning 14,392K shares, a decrease of 1.59%. However, their allocation in PACB has increased by 32.41% in the last quarter.

The ARK Genomic Revolution ETF, ARKG, holds 11,696K shares, equivalent to 4.48% ownership of the company. In their prior filing, the firm reported owning 12,014K shares, a decrease of 2.71%. Nevertheless, their portfolio allocation in PACB has increased by 121.73% in the last quarter.

Pacific Biosciences of California is known for its cutting-edge instruments that are built on Single Molecule, Real-Time (SMRT®) Sequencing technology. This technology provides a comprehensive understanding of genomes, transcriptomes, and epigenomes, granting access to the full range of genetic variation in any organism. The company’s PacBio® sequencing systems have been widely used by researchers globally, leading to numerous discoveries in human biomedical research, plant and animal sciences, and microbiology. These discoveries have been